Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Innovent Reports Positive Results from Phase III NSCLC Trial of PD-1 Drug

publication date: May 7, 2020

Suzhou Innovent Bio announced its approved anti-PD-1 drug, Tyvyt® (sintilimab injection), met its progression-free primary endpoint in a China Phase III trial in patients with non-small cell lung cancer. Tyvyt® was administered in combination with Gemzar® and platinum chemotherapy in first-line advanced or metastatic squamous non-small cell lung cancer (sqNSCLC). In January, Innovent released positive results from a similar NSCLC trial testing Tyvyt with ALIMTA® and platinum chemotherapy. The company's China NDA based on the earlier trial has been accepted for review. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.